Effects of intestinal and graft liver CYP3A5 genotypes on the C/D ratio of tacrolimus coadministered with omeprazole (n = 35) or lansoprazole (n = 54)
Data are expressed as median (range). *1 carriers, CYP3A5*1/*1 or *1/*3; *1 noncarriers, CYP3A5*3/*3.
PPI | Variables | CYP3A5 Genotype | P | ||
|---|---|---|---|---|---|
| *1 Carriers | *1 Noncarriers | ||||
| Omeprazole | Native intestine | ||||
| n | 11 | 24 | |||
| Tacrolimus C/D ratio | 1.96 (1.04-7.10) | 2.34 (0.52-22.9) | 0.47 | ||
| Graft liver | |||||
| n | 14 | 21 | |||
| Tacrolimus C/D ratio | 1.93 (0.52-7.10) | 2.54* (1.55-22.9) | 0.034 | ||
| Lansoprazole | Native intestine | ||||
| n | 18 | 36 | |||
| Tacrolimus C/D ratio | 1.97 (0.98-11.7) | 3.85* (0.72-13.4) | 0.015 | ||
| Graft liver | |||||
| n | 16 | 38 | |||
|
| Tacrolimus C/D ratio | 1.73 (0.72-11.1) | 2.85* (0.98-113.4) | 0.049 | |
↵* P < 0.05, *1 carriers versus *1 noncarriers (U test).